Physician profile
Daniel Laurden Bernabe
NPI 1912354283
$4,397.82
in general payments reported to CMS, 2019-2025
37 companies · $587 in 2025
The $587 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $716 · 2021: $831 · 2022: $597 · 2023: $575 · 2024: $563 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,725.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $603.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $546.54 | 2019-2025 | Ofev, Jardiance, Cyltezo |
| Lilly USA, LLC | $409.24 | 2019-2025 | Mounjaro, Zepbound, Taltz |
| Abbvie INC. | $378.09 | 2021-2025 | Qulipta |
| Astrazeneca Pharmaceuticals LP | $352.10 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $252.37 | 2019-2024 | |
| Amgen INC. | $250.93 | 2019-2025 | Evenity, Prolia |
| Glaxosmithkline, LLC. | $170.69 | 2019-2023 | Shingrix, Arexvy, Bexsero |
| Merck Sharp & Dohme LLC | $146.70 | 2019-2021 | |
| Horizon Therapeutics Plc | $125.06 | 2020-2021 | |
| Ucb, INC. | $107.40 | 2025 | Bimzelx |
| Janssen Pharmaceuticals, INC | $96.97 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $81.43 | 2023-2025 | |
| Abbott Laboratories | $80.81 | 2021-2023 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.37 | 2020-2024 | Trulance, Xifaxan |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Bernabe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.